Specific Diagnostics is a medical device startup that has developed in vitro diagnostic systems for the detection and identification of microorganisms while they grow in culture.
Specific Diagnostics' unique, patented chemical sensor array technology enables cost-effective diagnostic products that simplify workflow and speed time-to-answer.
Specific Diagnostics was founded in 2009 by Paul Rhodes & Ray Martino and is based in Mountain View, California.
Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Its products utilize sensor arrays to detect growth and quantify antibiotic efficacy with simple, automated instruments and disposables.
Specific’s Reveal™ system delivers phenotypic antimicrobial susceptibility testing (AST) results in an average of 5 hours, directly from positive blood culture or isolates. Based on standard 96-well microdilution panels, Reveal is affordable and provides accurate minimum inhibitory concentration (MIC) results with wide antimicrobial coverage.
Specific’s novel, patented Small Molecule Sensor (SMS) arrays™ respond to the small, volatile, metabolic components produced by microorganisms to detect growth, assess antibiotic efficacy, and determine microorganism ID.
Specific Diagnostics has received over $25M grant from CARB-X & NIH. They've also partnered with CARB-X, who are investing $455 million over five years into the research and development of new antibiotics, rapid diagnostics and other life-saving products to tackle the global threat of drug-resistant bacteria. Specific has also partnered with FIND, to make a global impact.
Specific Diagnostics has received $12.5M in a venture round on Sep 6, 2019, backed by Telegraph Hill Partners.